Angiopoietin-like proteins and postprandial partitioning of fatty acids.
Journal
Current opinion in lipidology
ISSN: 1473-6535
Titre abrégé: Curr Opin Lipidol
Pays: England
ID NLM: 9010000
Informations de publication
Date de publication:
01 02 2022
01 02 2022
Historique:
pubmed:
19
11
2021
medline:
3
5
2022
entrez:
18
11
2021
Statut:
ppublish
Résumé
Over the last two decades, evolving discoveries around angiopoietin-like (ANGPTL) proteins, particularly ANGPTL3, ANGPTL4, and ANGPTL8, have generated significant interest in understanding their roles in fatty acid (FA) metabolism. Until recently, exactly how this protein family regulates lipoprotein lipase (LPL) in a tissue-specific manner to control FA partitioning has remained elusive. This review summarizes the latest insights into mechanisms by which ANGPTL3/4/8 proteins regulate postprandial FA partitioning. Accumulating evidence suggests that ANGPTL8 is an insulin-responsive protein that regulates ANGPTL3 and ANGPTL4 by forming complexes with them to increase or decrease markedly their respective LPL-inhibitory activities. After feeding, when insulin levels are high, ANGPTL3/8 secreted by hepatocytes acts in an endocrine manner to inhibit LPL in skeletal muscle, whereas ANGPTL4/8 secreted by adipocytes acts locally to preserve adipose tissue LPL activity, thus shifting FA toward the fat for storage. Insulin also decreases hepatic secretion of the endogenous ANGPTL3/8 inhibitor, apolipoprotein A5 (ApoA5), to accentuate ANGPTL3/8-mediated LPL inhibition in skeletal muscle. The ANGPTL3/4/8 protein family and ApoA5 play critical roles in directing FA toward adipose tissue postprandially. Selective targeting of these proteins holds significant promise for the treatment of dyslipidemias, metabolic syndrome, and their related comorbidities.
Identifiants
pubmed: 34789669
doi: 10.1097/MOL.0000000000000798
pii: 00041433-202202000-00006
doi:
Substances chimiques
ANGPTL3 protein, human
0
ANGPTL8 protein, human
0
Angiopoietin-Like Protein 3
0
Angiopoietin-Like Protein 8
0
Angiopoietin-like Proteins
0
Angiopoietins
0
Fatty Acids
0
Insulins
0
Peptide Hormones
0
Lipoprotein Lipase
EC 3.1.1.34
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
39-46Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Harris DN, Ruczinski I, Yanek LR, et al. Evolution of hominin polyunsaturated fatty acid metabolism: from Africa to the new world. Genome Biol Evol 2019; 11:1417–1430.
Kovrov O, Kristensen KK, Larsson E, et al. On the mechanism of angiopoietin-like protein 8 for control of lipoprotein lipase activity. J Lipid Res 2019; 60:783–793.
Chen YQ, Pottanat TG, Siegel RW, et al. Angiopoietin-like protein 8 differentially regulates ANGPTL3 and ANGPTL4 during postprandial partitioning of fatty acids. J Lipid Res 2020; 61:1203–1220.
O’Neill S, O’Driscoll L. Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. Obes Rev 2015; 16:1–12.
Rashid S, Uffelman KD, Lewis GF. The mechanism of HDL lowering in hypertriglyceridemic, insulin-resistant states. J Diabetes Complications 2002; 16:24–28.
Seidell JC, Halberstadt J. Obesity: the obesity epidemic in the USA - no end in sight? Nat Rev Endocrinol 2016; 12:499–500.
Zhang R. The ANGPTL3-4-8 model, a molecular mechanism for triglyceride trafficking. Open Biol 2016; 6:150272.
Bini S, D’Erasmo L, Di Costanzo A, et al. The interplay between angiopoietin-like proteins and adipose tissue: another piece of the relationship between adiposopathy and cardiometabolic diseases? Int J Mol Sci 2021; 22:742.
Morelli MB, Chavez C, Santulli G. Angiopoietin-like proteins as therapeutic targets for cardiovascular disease: focus on lipid disorders. Expert Opin Ther Targets 2020; 24:79–88.
Wu SA, Kersten S, Qi L. Lipoprotein lipase and its regulators: an unfolding story. Trends Endocrinol Metab 2021; 32:48–61.
Péterfy M. Lipase maturation factor 1: a lipase chaperone involved in lipid metabolism. Biochim Biophys Acta 2012; 1821:790–794.
Young SG, Fong LG, Beigneux AP, et al. GPIHBP1 and lipoprotein lipase, partners in plasma triglyceride metabolism. Cell Metab 2019; 30:51–65.
Birrane G, Beigneux AP, Dwyer B, et al. Structure of the lipoprotein lipase-GPIHBP1 complex that mediates plasma triglyceride hydrolysis. Proc Natl Acad Sci U S A 2019; 116:1723–1732.
Nimonkar AV, Weldon S, Godbout K, et al. A lipoprotein lipase-GPI-anchored high-density lipoprotein-binding protein 1 fusion lowers triglycerides in mice: Implications for managing familial chylomicronemia syndrome. J Biol Chem 2020; 295:2900–2912.
Goulbourne CN, Gin P, Tatar A, et al. The GPIHBP1-LPL complex is responsible for the margination of triglyceride-rich lipoproteins in capillaries. Cell Metab 2014; 19:849–860.
Beigneux AP, Davies BS, Gin P, et al. Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons. Cell Metab 2007; 5:279–291.
Beigneux AP, Allan CM, Sandoval NP, et al. Lipoprotein lipase is active as a monomer. Proc Natl Acad Sci U S A 2019; 116:6319–6328.
Wolska A, Reimund M, Remaley AT. Apolipoprotein C-II: the re-emergence of a forgotten factor. Curr Opin Lipidol 2020; 31:147–153.
Surendran RP, Visser ME, Heemelaar S, et al. Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia. J Intern Med 2012; 272:185–196.
Köster A, Chao YB, Mosior M, et al. Transgenic angiopoietin-like (angptl)4 overexpression and targeted disruption of angptl4 and angptl3: regulation of triglyceride metabolism. Endocrinology 2005; 146:4943–4950.
Aryal B, Price NL, Suarez Y, Fernández-Hernando C. ANGPTL4 in metabolic and cardiovascular disease. Trends Mol Med 2019; 25:723–734.
Gutgsell AR, Ghodge SV, Bowers AA, Neher SB. Mapping the sites of the lipoprotein lipase (LPL)-angiopoietin-like protein 4 (ANGPTL4) interaction provides mechanistic insight into LPL inhibition. J Biol Chem 2019; 294:2678–2689.
Leth-Espensen KZ, Kristensen KK, Kumari A, et al. The intrinsic instability of the hydrolase domain of lipoprotein lipase facilitates its inactivation by ANGPTL4-catalyzed unfolding. Proc Natl Acad Sci U S A 2021; 118:e2026650118.
Kristensen KK, Leth-Espensen KZ, Kumari A, et al. GPIHBP1 and ANGPTL4 utilize protein disorder to orchestrate order in plasma triglyceride metabolism and regulate compartmentalization of LPL activity. Front Cell Dev Biol 2021; 9:702508.
Kristensen KK, Leth-Espensen KZ, Mertens HDT, et al. Unfolding of monomeric lipoprotein lipase by ANGPTL4: insight into the regulation of plasma triglyceride metabolism. Proc Natl Acad Sci U S A 2020; 117:4337–4346.
Lichtenstein L, Mattijssen F, de Wit NJ, et al. Angptl4 protects against severe proinflammatory effects of saturated fat by inhibiting fatty acid uptake into mesenteric lymph node macrophages. Cell Metab 2010; 12:580–592.
Desai U, Lee EC, Chung K, et al. Lipid-lowering effects of antiangiopoietin-like 4 antibody recapitulate the lipid phenotype found in angiopoietin-like 4 knockout mice. Proc Natl Acad Sci U S A 2007; 104:11766–11771.
Oteng AB, Ruppert PMM, Boutens L, et al. Characterization of ANGPTL4 function in macrophages and adipocytes using Angptl4-knockout and Angptl4-hypomorphic mice. J Lipid Res 2019; 60:1741–1754.
Cushing EM, Chi X, Sylvers KL, et al. Angiopoietin-like 4 directs uptake of dietary fat away from adipose during fasting. Mol Metab 2017; 6:809–818.
Spitler KM, Shetty SK, Cushing EM, et al. Regulation of plasma triglyceride partitioning by adipose-derived ANGPTL4 in mice. Sci Rep 2021; 11:7873.
Ruppert PMM, Michielsen CCJR, Hazebroek EJ, et al. Fasting induces ANGPTL4 and reduces LPL activity in human adipose tissue. Mol Metab 2020; 40:101033.
Wang Y, Quagliarini F, Gusarova V, et al. Mice lacking ANGPTL8 (Betatrophin) manifest disrupted triglyceride metabolism without impaired glucose homeostasis. Proc Natl Acad Sci U S A 2013; 110:16109–16114.
Quagliarini F, Wang Y, Kozlitina J, et al. Atypical angiopoietin-like protein that regulates ANGPTL3. Proc Natl Acad Sci U S A 2012; 109:19751–19756.
Zhang R. Lipasin: a novel nutritionally-regulated liver-enriched factor that regulates serum triglyceride levels. Biochem Biophys Res Commun 2012; 424:786–792.
Chi X, Britt EC, Shows HW, et al. ANGPTL8 promotes the ability of ANGPTL3 to bind and inhibit lipoprotein lipase. Mol Metab 2017; 6:1137–1149.
Haller JF, Mintah IJ, Shihanian LM, et al. ANGPTL8 requires ANGPTL3 to inhibit lipoprotein lipase and plasma triglyceride clearance. J Lipid Res 2017; 58:1166–1173.
Ren G, Kim JY, Smas CM. Identification of RIFL, a novel adipocyte-enriched insulin target gene with a role in lipid metabolism. Am J Physiol Endocrinol Metab 2012; 303:E334–E351.
Nidhina-Haridas PA, Soronen J, Sädevirta S, et al. Regulation of angiopoietin-like proteins (ANGPTLs) 3 and 8 by insulin. J Clin Endocrinol Metab 2015; 100:E1299–E1307.
Baroukh N, Bauge E, Akiyama J, et al. Analysis of apolipoprotein A5, c3, and plasma triglyceride concentrations in genetically engineered mice. Arterioscler Thromb Vasc Biol 2004; 24:1297–1302.
Sharma V, Ryan RO, Forte TM. Apolipoprotein A-V dependent modulation of plasma triacylglycerol: a puzzlement. Biochim Biophys Acta 2012; 1821:795–799.
Chen YQ, Pottanat TG, Zhen EY, et al. ApoA5 lowers triglyceride levels via suppression of ANGPTL3/8-mediated LPL inhibition. J Lipid Res 2021; 62:100068.
Nowak M, Helleboid-Chapman A, Jakel H, et al. Insulin-mediated down-regulation of apolipoprotein A5 gene expression through the phosphatidylinositol 3-kinase pathway: role of upstream stimulatory factor. Mol Cell Biol 2005; 25:1537–1548.
Chen YQ, Pottanat TG, Siegel RW, et al. Angiopoietin-like protein 4(E40K) and ANGPTL4/8 complex have reduced, temperature-dependent LPL-inhibitory activity compared to ANGPTL4. Biochem Biophys Res Commun 2021; 534:498–503.
Dewey FE, Gusarova V, O’Dushlaine C, et al. Inactivating variants in ANGPTL4 and risk of coronary artery disease. N Engl J Med 2016; 374:1123–1133.
Gusarova V, O’Dushlaine C, Teslovich TM, et al. Genetic inactivation of ANGPTL4 improves glucose homeostasis and is associated with reduced risk of diabetes. Nat Commun 2018; 9:2252.
Singh AK, Chaube B, Zhang X, et al. Hepatocyte-specific suppression of ANGPTL4 improves obesity-associated diabetes and mitigates atherosclerosis in mice. J Clin Invest 2021; 13:140989.
Arca M, D’Erasmo L, Minicocci I. Familial combined hypolipidemia: angiopoietin-like protein-3 deficiency. Curr Opin Lipidol 2020; 31:41–48.
Su X. ANGPLT3 in cardio-metabolic disorders. Mol Biol Rep 2021; 48:2729–2739.
Dewey FE, Gusarova V, Dunbar RL, et al. Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. N Engl J Med 2017; 377:211–221.
Raal F, Rosenson RS, Reeskamp LF, et al. ELIPSE HoFH Investigators. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med 2020; 383:711–720.
Reeskamp LF, Millar JS, Wu L, et al. ANGPTL3 inhibition with evinacumab results in faster clearance of IDL and LDL apoB in patients with homozygous familial hypercholesterolemia-brief report. Arterioscler Thromb Vasc Biol 2021; 41:1753–1759.
Markham A. Evinacumab: first approval. Drugs 2021; 81:1101–1105.
Adam RC, Mintah IJ, Alexa-Braun CA, et al. Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance. J Lipid Res 2020; 61:1271–1286.
Helkkula P, Kiiskinen T, Havulinna AS, et al. ANGPTL8 protein-truncating variant associated with lower serum triglycerides and risk of coronary disease. PLoS Genet 2021; 17:e1009501.
Oldoni F, Bass K, Kozlitina J, et al. Genetic and metabolic determinants of plasma levels of ANGPTL8. J Clin Endocrinol Metab 2021; 106:1649–1667.
Gusarova V, Banfi S, Alexa-Braun CA, et al. ANGPTL8 blockade with a monoclonal antibody promotes triglyceride clearance, energy expenditure, and weight loss in mice. Endocrinology 2017; 158:1252–1259.
Oldoni F, Cheng H, Banfi S, et al. ANGPTL8 has both endocrine and autocrine effects on substrate utilization. JCI Insight 2020; 5:e138777.
Banfi S, Gusarova V, Gromada J, et al. Increased thermogenesis by a noncanonical pathway in ANGPTL3/8-deficient mice. Proc Natl Acad Sci U S A 2018; 115:E1249–E1258.
Jin N, Matter WF, Michael LF, et al. The angiopoietin-like protein 3 and 8 complex interacts with lipoprotein lipase and induces LPL cleavage. ACS Chem Biol 2021; 16:457–462.
Shu X, Nelbach L, Weinstein MM, et al. Intravenous injection of apolipoprotein A-V reconstituted high-density lipoprotein decreases hypertriglyceridemia in apoav-/- mice and requires glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1. Arterioscler Thromb Vasc Biol 2010; 30:2504–2509.